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Abstract
Aims: Opioid use disorder (OUD) is associated with significant morbidity and mortality,
and opioid agonist treatment (OAT) with methadone or buprenorphine represents the
most efficacious treatment. However, data suggest that chronic administration of opioids
may be associated with significant weight gain, possibly by altering an organism’s
perception of and preference for sweet foods. The primary aim of this laboratory study
was to rigorously examine sucrose subjective response among adults receiving OAT and
a comparison sample without OUD. As secondary outcomes, we also sought to compare
the groups on additional baseline characteristics that may influence subjective sucrose
response and weight gain during treatment.
Methods: Participants were 40 adults receiving treatment for OUD (OUD+) and a
comparison sample of 40 adults without OUD (OUD-). All participants completed an
initial screening visit that included questionnaires on eating behaviors, diet and nutrition,
recent substance use, and measurement of body mass index. Eligible participants
completed two, same-day outpatient laboratory sessions during which they sampled six
experimenter-administered concentrations of sucrose solution (0, 0.1, 0.25, 0.5, 0.75, and
1.0M in distilled water) each three times under double-blind counterbalanced conditions.
Following each exposure, participants rated the pleasantness and intensity of each sample
using 100-point visual analog scales.
Results: OUD+ participants rated sucrose solutions as less pleasant than OUDparticipants (p<0.001). However, this effect was limited to the three lowest sucrose
concentrations (0, 0.1, 0.25M), and at higher concentrations there were no group
differences. There were no between-group differences on ratings of intensity (p=0.35).
Given these baseline group differences in placebo (0M) responding, sucrose response was
also examined in terms of change from baseline. In this analysis, there was a significant
group effect, with a higher magnitude of change in pleasantness ratings and a lower
magnitude of change in intensity ratings from 0M in OUD+ vs. OUD- participants
(p’s<0.05). With regard to baseline characteristics that may influence sucrose response
and eating behavior more generally, the OUD+ group had a higher prevalence of obesity,
food insecurity, unhealthy eating behaviors, high sugar consumption, and nutrition
knowledge deficits compared to the OUD- group (p’s<0.05).
Conclusion: Data from preclinical and clinical research have suggested that opioid
agonist medications may enhance subjective response to sweet flavors. In the present
study, OUD+ participants exhibited a higher magnitude of change in pleasantness ratings
from placebo compared to OUD- participants. However, this effect was largely driven by
pronounced group differences in perceived pleasantness of essentially unsweet solutions.
On the outcome of sucrose intensity, findings were more mixed with no consistent
differences between OUD+ and OUD- participants. In contrast, group differences were
far more pronounced in participants’ daily eating behaviors and nutrition knowledge,
with OUD+ participants presenting with a consistently more severe profile. These data
highlight the significant risk factors experienced by OUD+ individuals that extend
beyond drug-related risks and may inform future scientific and clinical efforts to improve
health outcomes in this vulnerable population.
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1. Introduction
The current United States opioid epidemic represents the most devastating public
health crisis of our time, with nearly 12 million Americans reporting opioid misuse in
2016 (SAMHSA, 2017). Opioid use disorder (OUD) is associated with a multitude of
consequences including infectious disease, overdose and premature death, as well as
significant economic costs estimated at over $78 billion annually (Birnbaum et al., 2011;
Clausen, Waal, Thoresen, & Gossop, 2009; Gomes, Tadrous, Mamdani, Paterson, &
Juurlink, 2018; Hser, Hoffman, Grella, & Anglin, 2001; Scholl, Seth, Kariisa, Wilson, &
Baldwin, 2019).
Opioid agonist treatment (OAT) with methadone or buprenorphine is the most
efficacious treatment for OUD (Mattick, Breen, Kimber, & Davoli, 2014). Methadone is
a µ-opioid full agonist; whereas buprenorphine is a µ-opioid partial agonist that has a
distinct pharmacological profile characterized by a ceiling effect on its agonist activity, a
long plasma half-life, and slow dissociation from the µ-opioid receptor (Johnson, 2003;
Sigmon, Wong, Chausmer, Liebson, & Bigelow, 2004; Walsh, 2003). Maintenance
treatment with methadone or buprenorphine has been consistently shown to reduce illicit
opioid use, withdrawal symptoms, risky drug use behaviors, contraction of infectious
disease, overdoses, criminal activity and premature death (Mattick, Breen, Kimber, &
Davoli, 2009; Mattick et al., 2014; National Academies of Sciences, Engineering, and
Medicine, 2019; Volkow, Jones, Einstein, & Wargo, 2019).
Despite its undisputed efficacy for reducing morbidity and mortality associated
with OUD, OAT may also be associated with several adverse health effects. One that we
have become especially interested in is the possibility that chronic administration of
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opioids may be associated with significant weight gain. In a recent retrospective chart
review we examined body mass index (BMI) and weight changes among 96 patients
receiving methadone maintenance treatment at two timepoints: at treatment intake and
again approximately two years later (Fenn, Laurent, & Sigmon, 2015). We observed a
significant increase in BMI following entry into methadone treatment (p<0.001), with
mean BMIs increasing from 27.2±6.8 to 30.1±7.7 kg/m2 at Times 1 and 2, respectively.
This translated to an increase from 177.6 to 195.4 pounds, representing a 10% (17.8pound) increase in body weight. These data are consistent with several prior studies that
have found significant weight gains during OAT, particularly during treatment with
methadone. A recent study of 114 methadone-maintained patients in Israel, for example,
found significant weight gain early in treatment, with mean BMIs increasing 8% within
the first year of treatment (Peles, Schreiber, Sason, & Adelson, 2016). Among 55
methadone patients in Iran, a similar increase in BMI was detected within only the first
two months of treatment, with mean BMIs increasing by 7% and the percentage of
patients meeting criteria for obesity increasing from 3.6% to 7.2% during the eight weeks
following treatment entry (Montazerifar, Karajibani, & Lashkaripour, 2012). In a recent
study of 74 methadone patients in the U.S., 42% of patients met criteria for overweight,
obese, or morbidly obese at treatment entry; this increased to 76%, 82%, and 88% at one,
two, and three years post-intake, respectively (Sweeney et al., 2018). A single recent
study found similar weight gains during buprenorphine treatment, with 107 adult
inpatients in Turkey experiencing a mean body weight increase of 8% by the fourth
month of buprenorphine maintenance (p<0.001; Baykara & Alban, 2019). Overall, of the
13 published studies that have evaluated changes in weight during OAT, 92% have
2

reported statistically significant increases following OAT entry (Table 1). These
potential shifts of patients into overweight or obese categories may place patients at
heightened risk of developing cardiovascular disease, stroke, diabetes, cancer, and
premature death (Fenn et al., 2015; Mysels & Sullivan, 2010; Schlienz, Huhn, Speed,
Sweeney, & Antoine, 2018).
One possible explanation for these weight gains during treatment is that they may
simply be a function of undernourished illicit drug abusers moving toward a healthier
weight as they become stabilized in opioid treatment (Gronbladh & Ohlund, 2011;
Okruhlica & Slezakova, 2008). However, the data thus far do not strongly support this
explanation. Across the studies that have reported BMI changes during treatment,
patients generally moved from the normal (rather than underweight) category at intake to
an overweight or obese BMI following enrollment into OAT. In our recent investigation
in the methadone clinic, for example, patients were generally already in the overweight
category at treatment intake (BMIs 25.0-29.9 kg/m2) and transitioned into the obese
category (BMI >30.0 kg/m2) by the second assessment timepoint.
1.1 Potential opioid effects on sweet subjective response
Preclinical studies
Another possibility is that administration of opioid agonists may alter, and in
particular enhance, an organism’s perception of and preference for sweet foods (Mysels
& Sullivan, 2010). The most experimentally rigorous studies on this have been
conducted in non-human animals and have generally shown that experimenteradministered opioid agonists are associated with increased ingestion of sweetened
solutions or food (Castro & Berridge, 2017; Comer, Evans, Pudiak, & Foltin, 2002;
3

Daniels, Pratt, Zhou, & Leri, 2018; Gagin, Cohen, & Shavit, 1996; Pecina & Berridge,
2005; Zhang & Kelley, 2002). In a recent study examining the effect of methadone
administration on consumption of rat chow and a liquid high fructose corn syrup solution,
for example, methadone concurrently decreased intake from chow and increased intake of
the sweetened solution (Daniels et al., 2018). In another, microinjection of a µ-opioid
agonist in rats potentiated measures of liking of a sucrose solution by 200-300% and
increased sweet food consumption (Castro & Berridge, 2017).
Providing further evidence of a potential pharmacological effect of opioid
agonists on individuals’ subjective response to sweet taste, administration of opioid
antagonists (e.g., naltrexone, naloxone) has been shown to reduce preference for and
intake of sweetened solutions and foods (Kirkham, 1990; Levine, Weldon, Grace, Cleary,
& Billington, 1995; Rockwood & Reid, 1982; Yirmiya, Lieblich, & Liebeskind, 1988).
For example, naltrexone administration has been associated with reduced preference for
and intake of saccharin solution in mice (Yirmiya et al., 1988). In a later study, naloxone
reduced intake of sweetened vs. normal chow in both food-deprived and 50% satiated rats
(Levine et al., 1995).
Clinical studies
While the pre-clinical evidence with opioid agonists and antagonists has generally
supported a potential pharmacological mechanism underlying the influence of opioids on
sweet subjective response, the clinical data on this topic have been more mixed. Those
studies have generally utilized an experimental procedure called a sweet taste test,
wherein individuals sample a variety of sucrose solutions under double-blind conditions
and then rate the pleasantness (i.e., self-reported liking) and intensity (i.e., self-reported
4

sweetness) of each concentration. Two such studies have been conducted evaluating
sweet taste response among individuals maintained on methadone or buprenorphine for
treatment of OUD (Bogucka-Bonikowska et al., 2002; Green et al., 2013). In the first, 28
male methadone-maintained patients and a comparison sample of 32 male adults without
a history of OUD sampled three solutions that varied in sucrose concentration (ranging
from 0M to 0.88M) as well as a negative control solution (i.e., 0M sucrose) (BoguckaBonikowska et al., 2002). A small amount (10mL) of each solution was administered
once on the tongue via a syringe in counterbalanced order across subjects. Following
each exposure, participants rated the solution’s pleasantness (-50 to +50) and intensity (0
to 100) on a 100mm visual analog scale (VAS). There were no significant betweengroup differences in ratings of sweet pleasantness or intensity for any sucrose solution.
However, in the dietary information collected from both groups at study screening, the
methadone-maintained group did report adding significantly more sugar to beverages
than controls (2.3 vs. 1.3 spoonfuls per cup, respectively).
In the second study, 14 patients receiving OAT (7 methadone, 7 buprenorphine)
and a comparison sample of 65 adults without a history of illicit drug use sampled each of
10 sucrose concentrations ranging from 1.0 millimolar (mM) to 1.0 molar (M) sucrose
per liter (L) of distilled water (Green et al., 2013). Each solution was administered five
times on the tip of the tongue via cotton swab under double-blind counterbalanced
conditions to determine sweet taste threshold, which was operationalized as the
concentration at which the participant could detect the solution in 2.5 of 5 (50%)
presentations. For the measures of sweet pleasantness and intensity, participants swished
5mL of the highest sucrose solution (1.0M) in their mouth. They then rated the solution’s
5

taste pleasantness (-50 to +50) and intensity (0 to 100). Sucrose threshold recognition
ratings were significantly greater in the OMT vs. comparison participants. That is, larger
concentrations of sucrose (equal to about 3-4 teaspoons of sugar per mug) were needed
for the OMT group to detect sweet taste. Among OMT participants, methadone dose was
significantly and positively correlated with sucrose threshold recognition. Ratings of
sweet pleasantness and intensity for the largest sucrose concentration (1.0M) were
significantly (approximately three- and two-fold, respectively) greater in the opioidmaintained vs. comparison group.
Two additional clinical studies examined the effects of both opioid agonists and
antagonists on sweet subjective response (Eikemo et al., 2016; Langleben, Busch,
O’Brien, & Elman, 2012). In the first, 15 recently-detoxified heroin users sampled 5
sucrose concentrations (ranging from 0.05 to 0.83M) three times each and provided
ratings of sweet taste pleasantness, intensity, and wanting (i.e., extent that they want to
have more of the sample) before and after an injection of extended-release naltrexone
(Langleben et al., 2012). Compared to the pre-naltrexone baseline, ratings for sweet taste
pleasantness were significantly reduced one week after the naltrexone injection. The
second study was a randomized, double-blind, placebo-controlled study comparing acute
morphine vs. naltrexone administration on sweet taste ratings and intensity in 49 male
adults without a history of OUD (Eikemo et al., 2016). Participants sampled five sucrose
concentrations (ranging 0.05 to 0.65M) three times each and rated sweet pleasantness and
intensity. These sucrose exposures occurred following acute administration of morphine
(10 mg), naltrexone (50 mg), or placebo. Participants’ ratings of sweet pleasantness in
response to the highest sucrose concentration (0.65M) were significantly greater
6

following morphine administration vs. naltrexone and placebo. In contrast, there were no
effects of drug administration on participant ratings of sweet intensity. Contrary to
hypotheses, however, ratings of sweet pleasantness following the two lowest sucrose
concentrations (0.05 and 0.10M) were actually higher during the naltrexone vs. morphine
and placebo conditions, suggesting the association between opioids and sweet subjective
response may vary as a function of sucrose concentration and highlighting the importance
of evaluating multiple concentrations.
1.2 Nutrition and eating behavior
These data suggesting that administration of opioid agonist medications may
increase individuals’ liking of and preference for sweetened foods is generally consistent
with the larger nutrition literature reporting that opioid-maintained individuals often
report elevated craving for and consumption of refined carbohydrates, particularly in the
form of the added sugars in desserts and other sweetened foods and beverages (Alves et
al., 2011; Gambera & Clarke, 1976; Li., Ryan, & Neale, 2016; Nolan & Scagnelli, 2007;
Peles et al., 2016; Szpanowka-Wohn, Dłuzniewska, Groszek, & LangMłynarska, 2000;
Tomedi, Bogen, Hanusa, Wisner, & Bodnar, 2012; Zador, Wall, & Webster, 1996). In
one study of methadone-maintained females in Australia, for example, patients consumed
significantly more sugar per day compared to a nationally representative sample of
women (122g vs. 101g, respectively) (Zador et al., 1996). The contribution of sugar to
daily total energy intake was higher in the methadone-maintained vs. comparison group
(31% vs. 20%, respectively). Additional studies have found higher levels of sugar
consumption and craving among individuals with vs. without OUD (Morabia et al., 1989;
Nolan & Scagnelli, 2007; Tomedi et al., 2012).
7

1.3 Summary
Taken together, data suggest that opioid agonists may increase the liking and
consumption of sweetened foods, which may play a role in the significant weight gain
and place patients at risk for overweight, obesity and their related adverse health
consequences. This potential interaction is also important and timely given the
increasing numbers of individuals developing OUD and entering methadone or
buprenorphine maintenance treatment (Alderks, 2017; Wen, Hockenberry, & Pollack,
2018).
1.4 Current study
The prior studies evaluating the effects of opioids on sweet subjective response in
individuals with OUD have had several limitations. Nearly all focused on methadone,
rather than the partial agonist buprenorphine which is being increasingly used for
treatment of OUD (Volkow et al., 2019; Wen et al., 2018). Most of the study samples
were also exclusively (Bogucka-Bonikowska et al., 2002; Eikemo et al., 2016) or
predominantly (Langleben et al., 2012) male, limiting the generality of their findings to
females with OUD. This may be important as gender was the strongest predictor of BMI
changes in our prior study with methadone-maintained patients (Fenn et al., 2015), with
significantly greater BMI increases in females than males that translated to a 28-pound
(17.5%) increase in females vs. a 12-pound (6.4%) increase in males. Finally, the two
prior studies that have examined sweet intensity and pleasantness in opioid-maintained
patients did so using a limited number of sucrose concentrations (4 and 1, respectively;
Bogucka-Bonikowska et al., 2002; Green et al., 2013).

8

In the present laboratory study, we sought to improve upon these prior limitations
by evaluating sucrose subjective response among adults receiving OAT and a comparison
sample of adults without OUD using a larger sample than was used in previous studies.
We aimed to enroll generally comparable proportions of individuals receiving methadone
or buprenorphine treatment for OUD, as well as comparable numbers of males and
females. Additionally, we examined a wider range of sucrose concentrations than in
prior studies and also took care to control for timing of the sweet test procedure
administration in relation to OAT participants’ opioid dose timing (described more
below).
Primary aim
Our primary aim in this study was to compare sucrose subjective response among
adults receiving OAT for OUD (OUD+) and a comparison sample of adults without
opioid or other drug use disorders (OUD-). Under double-blind, counterbalanced
conditions, participants sampled six concentrations of sucrose (0, 0.1, 0.25, 0.5, 0.75, and
1.0M in distilled water) each three times and rated the pleasantness and intensity of each
sample. We hypothesized that, relative to the OUD- group, OUD+ participants would
have a steeper dose effect curve associated with pleasantness and intensity ratings across
the six sucrose concentrations, resulting in higher ratings at the highest concentration and
greater total area under the sucrose dose curve (AUC). To permit a rigorous evaluation
of subjective sucrose response at less risk of confounding by opioid dose timing,
participants in both groups completed the sweet taste test sessions twice. Specifically,
participants sampled and rated the six sucrose concentrations described above during two
same-day experimental sessions, scheduled three hours apart (corresponding to
9

approximate trough/peak medication levels for the OUD+ group).
Secondary aims
We also sought to examine additional baseline characteristics which may
influence eating behavior and weight gain among patients with OUD (Gambera &
Clarke, 1976; Nabipour, Said, & Habil, 2014; Neale, Nettleton, Pickering, & Fischer,
2012; Nolan & Scagnelli, 2007). As individuals with OUD and other substance use
disorders (SUDs) are particularly vulnerable to food insecurity and food insufficiency
(Himmelgreen et al., 1998; McLinden et al., 2018; Sigmon, 2016) and food insecurity is
associated with overeating, weight gain and obesity in the general population
(Dhurandhar, 2016; Kaiser, Dionne, & Carr, 2019; Rasmusson, Lydecker, Coffino,
White, & Grilo, 2019), we examined past-year food security. We also evaluated
measures related to eating behaviors, dietary intake and nutrition knowledge, as research
has suggested that these may be strongly associated with obesity and may also influence
development of SUD and treatment outcomes (Jeynes & Gibson, 2017; Richardson &
Wiest, 2015; Schroeder & Higgins, 2017). Overall, as these secondary outcomes were
more exploratory in nature, we did not propose directional hypotheses; however, they did
provide a unique opportunity to better understand how eating and nutrition related
behaviors and knowledge that are important in the general population may differ among
individuals with OUD.
2. Methods
2.1 Participants
Participants were 80 adults with (OUD+, n=40) and without (OUD-, n=40) OUD.
The primary referral source was IRB-approved flyers posted in the community as well as
10

local opioid treatment programs. Additional recruitment and referral sources included
referrals from community providers, public service announcements, and Facebook
advertisements. To be eligible, OUD+ participants had to be >18 years old, currently
receiving methadone or buprenorphine treatment for OUD and on a stable dose for >3
months. OUD- participants had to be >18 years old, generally healthy and without
current use of opioids or other illicit drugs. For both groups, individuals with a
significant psychiatric or medical illness that may interfere with consent or participation
were excluded, as were those who were pregnant or nursing. Individuals currently using
psychoactive medications including antidepressants in the monoamine oxidase inhibitor
and tricyclic classes, antipsychotics (e.g., haloperidol, pimozide, zotepine), mood
stabilizers (e.g., valproate or lithium), d-amphetamine and other stimulant medications,
and benzodiazepines were excluded, as these medications may impact taste function and
weight (Schlienz et al., 2018; Weafer, Lyon, Hedeker, & de Wit, 2017). Urine specimens
were collected at the intake screening visit (described below) and participants testing
positive for any drug other than prescribed allowable medication, cannabis, or cotinine
were also excluded. Consistent with prior studies on this topic (Eikemo et al., 2016;
Green et al., 2013), we also excluded individuals with high levels of caffeine, alcohol and
cigarette use as high doses of those drugs may modulate taste perception and sensitivity
to the reinforcing effects of sucrose (Choo, Picket, & Dando, 2017; Kampov-Polevoy,
Garbutt, & Janowsky, 1997; Pomerleau, Garcia, Drewnowski, & Pomerleau, 1991).
More specifically, those who reported caffeine intake exceeding 6 cups of coffee or
600mg caffeine per day, were physically dependent on alcohol, or smoked >20 cigarettes
per day were ineligible for the study. Individuals meeting the above criteria and
11

interested in the study were eligible to participate. Participants provided written
informed consent prior to participating.
2.2 Screening Session
Participants completed an initial eligibility screening assessment that consisted of
a Timeline Followback of past-month caffeine intake, opioid use, tobacco use, alcohol
use, and prescription and over-the-counter medication use (Sobell & Sobell, 1992), a
brief medical history and measurement of height, weight and BMI. Participants also
completed the Eating Behavior Questionnaire (Nolan & Scagnelli, 2007), the US Adult
Food Security Survey (Economic Research Service, USDA, 2012), NHANES Food
Frequency Questionnaire (CDC, 2017), Power of Food Scales (Lowe et al., 2009), and
the Nutrition Knowledge Questionnaire (Moynihan et al., 2007; Peles et al., 2016).
These instruments were administered either in pencil-and-paper format or via a secure,
IRB-approved online platform (Qualtrics, Provo, UT). Participants provided a urine
specimen analyzed on-site for opioids (i.e., methadone, buprenorphine, oxycodone,
hydrocodone, hydromorphone, heroin, fentanyl, morphine) and other drugs (i.e., cocaine,
amphetamines, benzodiazepines, marijuana, cotinine) via enzyme multiplied
immunoassay (EMIT; Microgenics, Fremont, CA). Finally, participants provided a
breath sample to assess for recent alcohol use (ALCO-SENSOR III, Intoximeters, Inc.,
St. Louis, MO). Participants received $30 for completing this initial screening session.
2.3 Measures
Screening Session Measures
Body Mass Index. Participants’ weight and height were measured at baseline to
calculate BMI. BMI is a widely-utilized measurement of the proportion of adiposity to
12

muscle mass in the body, which is calculated by dividing the mass in kilograms by height
in meters squared (kg/m2) (Fenn et al., 2015). Each participant’s BMI value was
categorized according to CDC criteria as underweight (BMI <18.5), normal weight (BMI
18.5 to <25), overweight (BMI 25.0 to <30) or obese (BMI >30.0) (CDC, 2017).
Food Security Survey. The US Adult Food Security Survey (FSS) is a 10-item
measure of past-year food security, which is defined as the availability and accessibility
to nutritionally adequate foods and food insecurity is a socioeconomic condition resulting
in uncertainty and lack of availability of nutritionally adequate food (Economic Research
Service, USDA, 2012). Response options are generally based on the self-reported
endorsement of a variety of experiences and behaviors related to low food availability for
a possible score range of 0-10. Individuals’ food security categories are determined from
this score and consist of high (score: 0), marginal (score: 1-2), low (score: 3-5) and very
low (score: 6-10) food security. Participants in the first two categories are considered to
be relatively food secure and those in the two latter categories as food insecure.
Eating Behavior Rating Questionnaire. The Eating Behavior Rating
Questionnaire (EBRQ) measures individuals’ self-reported frequency of healthy and
unhealthy eating habits (e.g., eating regular meals, maintaining a healthy diet and weight)
and preferences for consuming healthy (e.g., salad, meat) and unhealthy (e.g., candy,
pizza) food options. The EBRQ consists of 12 items and has been validated in samples
with OUD (Nolan & Scagnelli, 2007; Peles et al., 2016). Responses are indicated on a 5point Likert scale and total eating habit scores are calculated by summing ratings for the
12 items, for a possible range in scores from 12 (not healthy habits) to 60 (very healthy
habits). In addition, the EBRQ includes a final item, “do you feel like eating now?”
13

Participants endorsing this item then complete nine additional ratings measuring their
desire (0 (not at all) to 5 (extremely)) to eat a variety of specific foods and the amount (0
(none at all) to 5 (as much as I can hold)) that they would eat of that food item.
Food Frequency Questionnaire. The National Health and Nutrition
Examination Survey Food Frequency Questionnaire (CDC, 2017) examines individuals’
consumption of a comprehensive list of foods and beverages and has been widely used in
population-level research to estimate nutrient intake. Response options for its 139 items
focus on the frequency with which the participant consumes each food item in the past
year, ranging from never to daily. As the primary focus of this project was on
associations between opioids and sucrose response, we focused our analyses on the 24
items of the FFQ assessing frequency of sweet foods and beverages.
Nutrition Knowledge Questionnaire. The Nutrition Knowledge Questionnaire
(NKQ) has been used to characterize awareness of dietary standards and nutrient sources
in individuals with OUD and is of particular interest because it has been shown to be
associated with BMI in individuals receiving OAT (Moynihan et al., 2007; Peles et al.,
2016). The NKQ includes 15 items with a total score range from 0 to 47 (Moynihan et
al., 2007; Peles et al., 2016). This measure consists of 4 subscales, including: dietary
recommendations (score range: 0-17); nutrient sources (score range: 0-16); healthiest
meal option (score range: 0-4); and association between diet and disease (score range: 010).
Power of Food Scales. The Power of Food Scales (PFS) is a widely-established
measure that examines the thoughts, motivations, and perceptions related to appetite in an
environment in which palatable foods are readily available and has utility for predicting
14

individuals who experience elevated craving and overconsumption of palatable foods
(Lowe et al., 2009). Across 21 items, participants are asked to select how much they
agree that the items describe them on a scale of 1 (don’t agree at all) to 5 (strongly agree).
A total score is calculated by summing ratings across the items, with scores ranging from
21 to 105.
Yale Food Addiction Scale. The Yale Food Addiction Scale (YFAS) is a
widely-used measure in both clinical and non-clinical samples to identify individuals that
show markers of substance dependence with the consumption of foods high in fat and/or
sugar and thus risk for overweight and obesity (Gearhardt, Corbin, & Brownell, 2009;
Pursey, Stanwell, Gearhardt, Collins, & Burrows, 2014) including among those receiving
OAT for OUD (Sason, Adelson, Herzman-Harari, & Peles, 2018). The YFAS consists of
26 items assessing eating habits in the past year, with response options and resulting 8
criteria generally resembling DSM-IV symptoms for substance dependence (Gearhardt et
al., 2009). It been widely used with adults but was of interest to us given the recentlypublished study demonstrating an association between food addiction and
overweight/obesity among patients receiving methadone for OUD treatment (Sason et al.,
2018).
Pre-Session Measures
Upon arrival to each experimental session, participants completed a brief
questionnaire assessing the number of hours they slept the previous night and the
duration of time since their last food, caffeine, beverage, tobacco, and marijuana intake.
For the OUD+ group, research staff also recorded the exact time when they last took their
methadone or buprenorphine dose. Finally, participants completed the six subjective
15

state VAS items described previously evaluating current levels of happiness, sadness,
anxiety, sickness, nausea, and hunger.
2.4 Experimental Sessions
The study consisted of two outpatient laboratory sessions, both taking place on
the same day and approximately three hours apart. Participants were instructed to refrain
from consuming any alcohol 12 hours prior to Session 1 and to refrain from all food,
caffeine, tobacco, marijuana or beverages (except water) at least one hour prior to each
experimental session. They provided a urine specimen upon arrival to Session 1 and a
breath sample prior to each session, with any instances of recent alcohol use prompting a
rescheduling of that session. At the beginning of Session 1, participants also completed a
Timeline Followback of past day consumption of food and beverages, tobacco, caffeine,
marijuana, and prescribed and over-the counter drugs, and this was updated at Session 2
to reflect anything consumed between experimental sessions. Finally, at the beginning of
each session participants completed six visual analog scales (VAS) assessing baseline
mood and subjective states (i.e., happiness, sadness, anxiety, sickness, nausea, hunger).
Sucrose Taste Test
All sucrose solutions were prepared by the University of Vermont Medical
Center’s General Clinical Research Center from 50g medical grade sucrose powder
(QuinTron, Milwaukee, WI) in distilled water at room temperature. Prepared solutions
were then transferred to 2-ounce amber glass bottles and stored in a refrigerator at 37-40
degrees Fahrenheit, with the internal and external refrigerator temperatures monitored via
a digital monitor. Prepared solutions were stable for 60 days in refrigerated storage, after
which, they were discarded. The solutions were labeled with letters (A-F), with each
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letter corresponding to a single sucrose concentration. The solutions were administered
at room temperature during the experimental sessions.
Session 1. During the first experimental session, participants completed the presession activities described above and a research staff member oriented them to the
experimental procedures while supplies (e.g., pipette, cotton swabs, solutions) were laid
out next to them. Participants rinsed their mouth out with water and then sampled six
sucrose solutions (0, 0.1, 0.25, 0.5, 0.75, and 1.0M) three times each under double-blind
conditions and in counterbalanced order (Figure 1). Each solution was applied to the tip
of the tongue by research staff using a cotton bud, consistent with procedures used in
prior studies (e.g., Green et al., 2013). Participants then rated the solution’s pleasantness
and intensity using a 100mm VAS. The solution pleasantness scale (“How much do you
like this sample?”) ranged from 0 (dislike strongly) to 100 (like very much), with an
anchor at 50 (neutral: neither like nor dislike) and four additional anchors placed at
different segments on the scale (dislike moderately, dislike slightly and like slightly, like
moderately). The solution intensity scale (“How sweet is this sample?”) ranged from 0
(not at all) to 100 (extremely). Following completion of the VAS items, participants
rinsed their mouth with spring water before continuing onto the next solution. The intertrial interval between each sample was approximately 30 seconds in duration and the
overall session duration was approximately 30 minutes. For participants in the OUD+
group, this initial session took place immediately prior to ingestion of their daily
methadone or buprenorphine dose; for the OUD- group, this session took place in the
morning or early afternoon. At the end of Session 1, the time of Session 2 was confirmed
and participants were reminded not to consume any cannabis, tobacco, food or beverages
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(except water) at least one hour prior to the next session. OUD+ participants were asked
to take their usual methadone or buprenorphine dose as prescribed immediately following
the session and to record the time that they took their dose. Participants received $50 for
completing Session 1.
Session 2. The second experimental session took place approximately three hours
following completion of Session 1. Before completing the sucrose taste test, participants
completed the pre-session measures described above, and the TLFB was updated to
reflect any foods, beverages, cannabis, tobacco, and prescribed and over-the-counter
medications consumed between the experimental sessions. During Session 2, participants
again sampled the six sucrose solutions three times each under double-blind
counterbalanced conditions and rate each solution’s pleasantness and intensity following
sampling, as described above for Session 1. Participants were compensated $50 for
completing this second session.
2.5 Data analyses
The primary aim in this study was to compare sucrose subjective response
(pleasantness and intensity) across the 6 sucrose concentrations (0, 0.1, 0.25, 0.5, 0.75,
and 1.0M) among adults receiving OAT for OUD (OUD+) and a comparison sample of
adults without opioid or other drug use disorders (OUD-). Mixed model repeated
measures analyses (SAS, PROC MIXED) were used to compare groups and sessions
(Pre-Post dosing) on the primary outcome measure defined as area under the sucrose dose
curve (AUC) for subjective ratings of pleasantness and intensity. We also used mixed
model repeated measures analyses to compare groups and sessions on delta area under
the sucrose dose curve (DAUC), defined as the change in ratings of pleasantness and
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intensity at each sucrose dose from placebo. The model included one within-subject
fixed factor, session and two across-subject fixed factors, group (OUD+ vs. OUD-) and
order of solution presentation. Subject, nested within group and order, was a random
factor in the model. Additional mixed model analyses of variance were used to compare
OUD+ vs. OUD- groups on mean pleasantness and intensity ratings at each
concentration. Fisher’s LSD was used to perform pairwise comparisons both between
and within groups.
Additionally, multivariate analyses were conducted to examine predictors of
sucrose subjective response using stepwise linear regression. Entry criteria for inclusion
in the model was set at α=.05. The dependent variables for these analyses were AUC for
ratings of sucrose pleasantness and intensity. Candidate predictor variables were selected
based on the empirical literature. Age, gender, alcohol use, cigarette smoking, cannabis
use, pre-session mood ratings use, BMI, food insecurity, and OAT medication type were
considered as potential predictors as there was evidence from the literature that these may
be associated with sucrose subjective response and eating behaviors (Cornier et al., 2015;
Darmon & Drewnowski, 2008; Ettinger, Duizer, & Caldwell, 2012; Hardikar,
Höchenberger, Villringer, & Ohla, 2017; Krahn et al., 2006; Pomerleau, Garcia,
Drewnowski, & Pomerleau, 1991).
Finally, to examine several additional baseline characteristics which may
influence eating behavior and weight gain among patients receiving OAT, our secondary
outcome measures included: BMI, food security, eating behaviors, diet, and nutrition
knowledge. T-tests were used to compare groups on measures of body composition and
eating measures (BMI) and continuous demographic variables. T-tests were also used to
19

compare nutrition knowledge scores between groups and to compare groups on other
continuous secondary outcome measures (total scores and subscores on FSS, EBR, PFS,
etc.). Chi square tests were used for group comparisons on categorical outcome measures
(% meeting criterion on FSS and YFAS prevalence and FSS subcategories). All analyses
were performed using SAS statistical software Version 9.4 (SAS Institute, Cary, NC).
2.6 Sample size justification
Sample size estimates were based on detecting differences between OUD+ and
OUD- participants on our primary outcome measure, which corresponds to a difference
in the dose effect curve for ratings of pleasantness and intensity across sucrose
concentrations. The sample size of 40 participants/group was estimated to provide
sufficient power (80%) using α=.05 to detect an ES=0.65 (Cohen’s d) between the two
groups on ratings of pleasantness and intensity. This magnitude of difference is similar
to that observed by Green and colleagues (Green et al., 2013; d=0.72 for pleasantness and
smaller than that observed for intensity, ES=1.40). For secondary outcome measures,
this effect size of d=0.65 corresponds to a 4.3-unit (10%) decrease in EBR score, a 1.74
increase in FFS sum, and a 4.5-unit difference in BMI. For dichotomous outcomes such
as prevalence on the FSS or meeting criteria on YFAS or FSS subcategories, power was
estimated to be greater than 80% to detect an approximate 30% difference.
3. Results
3.1 Participant characteristics
Participant characteristics are presented in Table 2. OUD+ participants were
significantly older and had completed fewer years of education than OUD- participants
(p’s<0.01). Fewer OUD+ participants reported being employed full-time, and the OUD+
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group reported lower household income than the OUD- group (p's<0.001). With regard
to baseline drug use, a greater percentage of OUD+ participants reported past-month
tobacco and cannabis use relative to the OUD- group, while fewer OUD+ participants
reported past-month alcohol use (p's<0.001).
3.2 Session characteristics
As there were no significant differences between Sessions 1 and 2 for either
group, data have been collapsed across the two sessions. With regard to the ratings
collected at the beginning of each visit, with OUD+ participants reporting higher ratings
of Anxious, Sad and Nauseous and lower ratings of Happy relative to OUD- participants
(p’s<0.01; Table 3). The duration of time since last eating was greater for OUD+ than
OUD- and, of those who smoked, OUD+ participants reported a shorter interval since last
cigarette than OUD- participants (p’s<0.01). Sessions averaged 9 minutes in duration
and were longer for the OUD+ than OUD- group (9.5 ± 3.0 vs. 8.5 ± 1.4, respectively;
p<0.01). Finally, OUD+ participants completed Session 1 approximately 24 hours after
taking their prior day’s opioid medication dose and completed Session 2 approximately 3
hours after that day’s dose (not shown).
3.3 Subjective sucrose response
On the primary outcome of subjective sucrose response, there was a significant
group effect in ratings of pleasantness (“How much do you like this sample?”), with the
OUD+ group reporting less overall sucrose liking than the OUD- group (AUC: 49.6 ± 1.3
vs. 57.5 ± 1.3, p<0.001) (Figure 2, upper panel). When pleasantness ratings were
compared between groups at each sucrose concentration, OUD+ participants’ ratings of
liking were significantly lower than OUD- participants at the placebo (0M) dose and
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lowest sucrose concentrations (0.10M, and 0.25M, p’s<0.001) (Table 4). In contrast,
there was no difference between OUD+ and OUD- groups on ratings of intensity (“How
sweet is this sample?”) (AUC: 36.4 ± 2.0 vs. 39.1 ± 2.0, respectively, p=0.35) (Figure 2,
lower panel). Ratings of sucrose intensity for both groups increased in a dose-dependent
manner across sucrose concentrations (Table 4).
Considering the pronounced differences between groups in subjective
pleasantness response to placebo as noted above, we also examined participants’ sucrose
response as change from their placebo rating (i.e., subjective response to the 0M
solution). Using this approach, there was a significant group effect, with a higher
magnitude of change in pleasantness ratings from 0M in OUD+ vs. OUD- participants
(AUCD: 20.7 ± 1.9 vs. 12.6 ± 1.9, p<0.01) (Figure 3, upper panel) and a lower magnitude
of change in intensity ratings in OUD+ vs. OUD- (AUCD: 29.1 ± 1.9 vs. 35.6 ± 1.9,
p=0.02) (Figure 3, lower panel).
In multivariate analyses, group (OUD+, OUD-) was the only significant predictor
of subjective ratings of sucrose pleasantness (p=0.002), but did not predict sucrose
intensity (p=0.95); age, gender, alcohol use, cigarette smoking, cannabis use, and presession mood ratings were not associated with either subjective sucrose response
(p’s>0.05). Within the OUD+ group, there were no significant group differences
between those receiving methadone vs. buprenorphine in sucrose pleasantness (AUC:
36.4 ± 2.0 vs. 39.1 ± 2.0, p=0.35, not shown) or intensity (AUC: 36.4 ± 2.0 vs. 39.1 ±
2.0, p=0.35, not shown). Finally, sucrose response did not vary as a function of food
insecurity status or BMI (p’s>0.05).
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3.4 Baseline nutrition and eating behavior
As noted previously, we sought to examine additional baseline characteristics
associated with eating behaviors that may differ among patients with and without OUD.
With regard to BMI, there was a significant group effect on percentage of participants in
normal, overweight, and obese BMI categories (p=0.04) (Figure 4). A smaller percentage
of OUD+ participants had a BMI in the normal weight category relative to OUDparticipants (23% vs. 43%, respectively; p=0.06), while a greater percentage presented
with a BMI value in the obese range (45% vs. 20%, p=0.02). With respect to food
availability, prevalence of past-year food insecurity was significantly greater among
OUD+ vs. OUD- participants (50%. vs. 10%, p<0.001) (Figure 5). Group differences
were also seen in the distribution of participants across the four food security categories
(p<0.001), with fewer OUD+ participants reporting high food security relative to OUDparticipants (p<0.001) and significantly more reporting very low security (p<0.001).
In terms of eating behaviors, OUD+ participants presented with lower total scores
on the Eating Behavior Rating Questionnaire relative to OUD- participants (35.2 ± 6.1 vs.
43.4 ± 4.8, respectively; p<0.001). The OUD+ group consistently reported a lower
frequency of healthy individual habits (p’s<0.01) (Figure 6, top panel, left side) and a
higher frequency of unhealthy habits (p’s<0.01) (top panel, right side). Among the
subsets of participants that reported feeling like eating during the screening session (38%
and 50% in the OUD+ and OUD- groups, respectively), OUD+ participants generally
reported a significantly greater eagerness to consume unhealthy foods relative to OUDparticipants (p’s<0.05) (middle panel). They also reported a desire to consume larger
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amounts of unhealthy foods and smaller amounts of healthy foods (p’s<0.05) (lower
panel).
Similar outcomes were seen on the Food Frequency Questionnaire. Of the 23
sweet foods and beverages examined, the OUD+ group reported greater frequency of
consumption than OUD- participants on 17 items, including greater daily consumption of
6 sweetened food and beverages. (p’s<0.05) (Table 5). The Timeline Followback also
indicated that OUD+ participants consumed significantly greater amounts of sweetened
caffeinated beverages relative to OUD- (p’s<0.01), translating to 89g vs. 4g of sugar from
this source per day for OUD+ vs. OUD- participants, respectively (p<0.001) (Figure 7,
upper panel). In the OUD+ group, the largest source of added sugar was soda,
accounting for 64% of the total average added sugar from caffeinated beverages (lower
panel).
Regarding participants’ knowledge and awareness of nutritional information, total
scores on the Nutrition Knowledge Questionnaire were significantly lower in the OUD+
group, with OUD+ vs. OUD- participants answering 46% vs. 65% of items correctly
(p<0.001) (Table 6). The OUD+ group had significantly lower scores across all four
subscales (p’s<0.001), with particular knowledge deficits related to associations between
diet and disease.
Finally, with respect to food-related reinforcement, there were no significant
differences between OUD+ and OUD- participants’ scores on the Power of Food Scale
(46.1+20.3 and 46.8+15.6, respectively (p=0.86, not shown), which seeks to measure
thoughts and perceptions related to appetite for palatable foods. However, the percentage
of participants endorsing Yale Food Addiction Scale criteria was numerically higher
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among OUD+ participants for all eight criteria and significantly greater on two criteria
(Table 7). A similar pattern was seen on the portion of the Yale Food Addiction
questionnaire assessing problems with overconsuming and/or craving palatable foods
high in sugar and/or fat (Figure 8), wherein the percentages of OUD+ participants
endorsing problems with individual foods were numerically greater on almost all items
and significantly greater on two foods: soda (35% vs. 8%, p<0.01) and cheeseburgers
(25% vs. 8%, p=0.03).
4. Discussion
Data from preclinical and clinical research have suggested that opioid agonist
medications may enhance subjective response to sweet flavors, and this may place
opioid-dependent patients at risk for increased sugar consumption and subsequent weight
gain and related problems. In the present study, OUD+ participants exhibited a higher
magnitude of change in pleasantness ratings from placebo compared to OUDparticipants. However, this effect was largely driven by pronounced group differences in
participants’ perceived pleasantness of essentially unsweet solutions, with OUD+
participants rating the lowest concentration sucrose solutions as less pleasant than OUDparticipants. The only other study to evaluate a 0M sucrose concentration found no
significant differences in pleasantness ratings between males receiving methadone
maintenance treatment and a comparison sample without OUD (Bogucka-Bonikowska et
al., 2002). Our findings of no group differences at the higher sucrose concentrations are
generally consistent with a prior study in which there were no differences in perceived
sucrose pleasantness between males with and without OUD, including the highest
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concentration examined (0.88M) (Bogucka-Bonikowska et al., 2002; but see Green et al.,
2013).
On the measure of sucrose intensity, the findings were less clear. On the overall
AUC outcome measure, participants’ intensity ratings did not vary as a function of opioid
status, with both groups showing similar dose-dependent increases. However, OUD+
participants did exhibit a significantly lower magnitude of change in intensity ratings
from placebo compared to OUD- participants. Important to note, however, is that the
magnitude of group differences in change from placebo was less robust for sucrose
intensity than pleasantness. These results are generally consistent with a prior study
examining effects of methadone on subjective sucrose intensity, with no between-group
differences observed on ratings of intensity at the highest sucrose concentration
(Bogucka-Bonikowska et al., 2002). However, the opioid-maintained participants in the
prior study by Green and colleagues (2013) rated a 1.0M sucrose dose two-fold higher in
sweet intensity compared to adults without OUD. Methodological differences between
studies in how sucrose pleasantness and intensity were measured may contribute to these
differences. For example, the present study and the prior report by Bogucka-Bonikowska
and colleagues (2002) used an 100mm linear VAS for assessing sucrose subjective
ratings, while Green and colleagues (2013) used a Generalized Labeled Magnitude Scale
(170mm for pleasantness, 150mm for intensity) which uses a quasilogarithmic
positive/negative scale and may be more sensitive to between-group differences
(Bartoshuk et al., 2004).
Taken together, the data from this and several prior studies suggest that the
association between opioids and subjective sucrose response in humans may be less
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robust than has been seen in the pre-clinical literature, which has consistently shown a
large magnitude of effects of opioids on sweet preference of sweetened solutions and
foods (e.g., Berridge, 1996; Castro & Berridge, 2017; Zhang & Kelley, 2002). However,
also important to note is that pre-clinical experiments have often utilized choice
paradigms to evaluate sweet preference, which involve actual consumption of sweetened
solutions or foods vs. water or normal chow. Choice paradigms may assess more of the
“wanting” process of reinforcement (i.e., approach toward a food reward or motivation to
consume) rather than “liking” (i.e., palatability or pleasantness associated with a food),
two possibly independent though not mutually exclusive constructs (Berridge, 1996).
This may highlight the potentially complex mechanisms underlying our findings in this
study in which opioid-dependent individuals look remarkably similar to comparison
participants in terms of subjective ratings of sucrose pleasantness and intensity and yet
consistently choose sugar and sweetened foods and beverages over healthier alternatives
in their everyday lives (Alves et al., 2011; Gambera & Clarke, 1976; Nolan & Scagnelli,
2007; Tomedi et al., 2012; Zador et al., 1996). However, also critical to remember are
the many other complex factors influencing eating and so many other health behaviors
among opioid-dependent individuals (e.g., socioeconomic status, educational attainment,
co-occurring conditions).
We also sought to examine numerous additional baseline characteristics that may
influence sucrose response and eating behavior more generally among patients receiving
OAT, including BMI, food security, eating behaviors, diet, and nutrition knowledge.
OUD+ participants presented with a higher mean BMI relative to comparison participants
and nearly half were in the obese BMI category, which is consistent with prior studies on
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this topic by our group and others (Baykara & Alban, 2019; Fenn et al., 2015; Nolan &
Scagnelli, 2007; Sweeney et al., 2018). Despite a high prevalence of obesity in the
OUD+ group, half of the sample also experienced past-year food insecurity, with over a
third endorsing the most severe level. This is consistent with other studies in the general
population demonstrating that lower food security is paradoxically associated with
overeating and obesity (Dhurandhar, 2016; Kaiser et al., 2019; Rasmusson et al., 2019).
It is also consistent with previous studies reporting severe food insecurity among
individuals with OUD (Himmelgreen et al., 1998; McLinden et al., 2018; Strike,
Rudzinski, Patterson, & Millson, 2012).
OUD+ participants also presented with a markedly different profile of eating
behaviors compared to those without OUD, including greater consumption of unhealthy
foods as well as increased sugar craving and consumption (i.e., 89g sugar/day). This is
consistent with prior studies examining eating behaviors among individuals with OUD
(Alves et al., 2011; Gambera & Clarke, 1976; Nolan & Scagnelli, 2007; Peles et al.,
2016; Tomedi et al., 2012; Zador et al., 1996). This finding also generally aligns with the
earlier observations of enhanced sensitivity to sucrose pleasantness among our OUD+
participants. Peles and colleagues (2016) also reported that regular sweet food and
beverage consumption was associated with a higher BMI in MMT patients. OUD+
participants also had significantly lower nutrition knowledge relative to our comparison
group as well as previously published knowledge scores among MMT patients in Israel
(Peles et al., 2016; Sason et al., 2018). Knowledge deficits in the areas of healthy eating
may contribute to participants’ unhealthy eating behaviors and excessive sugar
consumption, as gaps in nutrition knowledge have been associated with a higher BMI and
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obesity in the general population (Moynihan et al., 2007; Valmórbida, Goulart, Busnello,
& Pellanda, 2017) as well as among adults with OUD more specifically (Peles et al.,
2016).
Finally, the OUD+ group reported having more problems with palatable foods
high in sugar (i.e., overeating, craving, trouble controlling consumption, tolerance,
interference of problem foods with psychosocial functioning). These data are consistent
with a recent study which examined loss-of-control (LOC) eating (i.e., perception that
one cannot control what or amount that one is eating) among 447 methadone-maintained
patients in the U.S. and found that a third endorsed LOC eating within the past 2 weeks
(Goldschmidt et al., 2018). Prevalence of recent LOC in that study was 3-fold higher
than in previous studies among community samples of adults (Goldschmidt et al., 2018;
Solmi, Hatch, Hotopf, Treasure, & Micali, 2014), and it was associated with greater
depressive symptoms, past-month illicit drug use, pain severity, and self-perception of
being overweight/obese. Similarly, in another recent study of patients receiving MMT,
10% met Yale criteria for food addiction and this was significantly associated with
weight gain during treatment (Sason et al., 2018).
Several methodological strengths of the present study are worth noting. First, our
sample of opioid-dependent participants was larger than those used in prior studies (e.g.,
N=14, Green et al., 2013; N=28, Bogucka-Bonikowska et al., 2002) and included similar
numbers of methadone- and buprenorphine-maintained individuals. Second, in an effort
to evaluate subjective sucrose response with less confounding by opioid dose timing,
participants in both groups completed the sweet taste test sessions twice, scheduled three
hours apart (corresponding to approximate trough/peak medication levels for the OUD+
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group). Third, we examined a larger range of sucrose concentrations than were evaluated
in prior studies (e.g., 1 concentration, Green et al., 2013; 4 concentrations, BoguckaBonikowska et al., 2002) and, unlike the study by Green and colleagues (2013), included
a 0M sucrose dose to permit an evaluation of baseline placebo responding.
Several limitations also merit mention. First, the two groups differed on a range
of baseline demographic and SES characteristics, including age, education, income, and
employment status, all of which may be associated with prevalence of food insecurity,
eating behaviors, diet, and BMI (Appelhans et al., 2012; Darmon & Drewnowski, 2008;
de Mestral, Chatelan, Marques-Vidal, Stringhini, & Bochud, 2019; Kaiser et al., 2019).
Thus, while these were not significant predictors of sucrose subjective response in our
study sample, they may contribute to the large between-group differences we observed in
prevalence of food insecurity and obesity as well as eating behaviors. Second, the study
was not sufficiently powered to detect differences in sucrose subjective response as a
function of OAT medication type (i.e., methadone vs. buprenorphine). While we were
able to conduct a preliminary evaluation of this important question, future studies should
more thoroughly investigate whether sucrose subjective response may vary as a function
of OAT medication. Finally, while we sought to examine as secondary outcomes the
associations between sucrose subjective response and other participant characteristics,
such as gender, BMI and food insecurity, our sample size for doing so was limited.
Overall, these differences in eating behaviors and knowledge may place opioiddependent individuals at elevated risk for a host of serious health consequences. There is
a significant association between sugar-sweetened beverage consumption and increased
incidence of mortality in the U.S. adults, with an 11% increase in all-cause mortality for
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each additional 12 oz. serving/day of a sugar-sweetened beverage (Collin, Judd, Safford,
Vaccarino, & Welsh, 2019). Through this lens, the mean amounts of sugar consumed by
our study sample in sugar-sweetened, caffeinated beverages alone translates to an
approximate 30% increase in all-cause mortality. Several studies have also found
elevated blood glucose levels and increased incidence of diabetes mellitus among patients
receiving methadone maintenance (Fareed, Byrd-Sellers, Vayalapalli, Drexler, &
Phillips, 2013; Reece, 2013; Vallecillo et al., 2018). Poor nutrition and unhealthy eating
behaviors can also adversely impact OUD treatment outcomes such as treatment
retention, illicit drug use and psychiatric symptoms (Goldschmidt et al., 2018;
Richardson & Wiest, 2015).
In summary, despite the well-established efficacy of OAT in reducing the
significant health and societal consequences associated with OUD, patients receiving
methadone or buprenorphine treatment may be at significant risk for obesity, diabetes,
cardiovascular disease, stroke, and premature death (Fenn et al., 2015; Mysels &
Sullivan, 2010; Schlienz et al., 2018). While OUD+ participants in this study
demonstrated generally similar subjective sucrose response, they presented with a
markedly different profile of everyday eating behaviors and knowledge than individuals
without SUDs. Efforts to understand and improve nutritional knowledge and eating
behaviors may improve health and opioid treatment outcomes in this vulnerable
population (Jeynes & Gibson, 2017; Nabipour et al., 2014).
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Table 1.
Published studies examining weight changes during opioid agonist treatment
Reference

Location

N

OAT Type

Baykara & Alban
(2019)

Turkey

107

buprenorphine

Significant increase in weight (8%)
from T0 to T4mos
Significant increases in weight
(10%) and BMI (11%) from T0 to
T2yrs

Fenn et al.
(2015)

US

96

methadone

Housova et al.
(2005)

Czech
Republic

12

methadone

Kabrt et al.
(1999)

Czech
Republic

14

methadone

Li et al.
(2016)

United
Kingdom

20

methadone,
buprenorphine

Montazerifar et
al.
(2012)

Iran

55

methadone

Mysels et al.
(2011)
Okruhlica &
Slezakova
(2008)

US

Slovakia

16

274

Outcomes

Significant increase in BMI (1%)
from T0 to T1yr
Significant increases in weight
(13%) and BMI (12%) from T0 to
T1.5yrs
Significant increase in BMI (1%)
from T0 to T1yr
Significant increase in weight (6%)
and BMI (7%) from T0 to T2mos

methadone

2% and 4% increases in weight
from T0 to T2mos and T6mos,
respectively

methadone

Increase in % of participants in BMI
categories from T0 to T1yr:
overweight (15% to 29%) and
obese categories (3% to 8%)
Significant increases in weight
(12% & 15%) and BMI (11% &
14%) from T0 to T1yr and to T4yrs,
respectively

Okruhlica &
Slezakova
(2012)

Slovakia

42

methadone

Parvaresh et al.
(2015)

Iran

200

methadone

Significant increase in weight (3%)
from T0 to T6mos

Peles et al.
(2016)

Israel

114

methadone

Significant increase in BMI (8%)
from T0 to T1yr

Reimer et al.
(2011)

Germany

1015

methadone

Significant increase in BMI (5%)
from T0 to T1yr

Sweeney et al.
(2019)

US

74

methadone

Significant increase in % of
participants in overweight, obese, or
morbidly obese BMI categories
from T0 (42%) to T1yr (76%), T2yrs
(82%), and T3yrs (88%)

Subscripts below timepoint (T) represent the duration of the interval reflected in the % of
weight and/or BMI change, with T0 representing the baseline timepoint.
32

Table 2.
Participant characteristics
OUD+
(n=40)

OUD(n=40)

p-value

Age, yrs

36.8 ± 10.0

30.6 ± 8.7

0.004

Male, %

53

50

0.823

Race, Caucasian Non-Hispanic, %

93

88

0.456

12.7 ± 1.5

14.9 ± 1.7

<0.001

23

75

<0.001

Education, yrs
Employed full-time, %
Annual median household income [IQR]

15000
35000
[5000,25000] [35000,75000]

<0.001

Alcohol consumption, % (N)

28 (11)

65 (26)

<0.001

# of days/past 30

11.3 ± 12.9

7.1 ± 7.7

0.23

# drinks per day

1.1 ± 1.4

0.54 ± 0.68

0.12

83 (33)

13 (5)

<0.001

# of days/past 30

28.8 ± 5.0

20.4 ± 13.1

0.01

# CPD

11.3 ± 6.3

4.1 ± 4.1

0.02

Caffeine use, % (N)

98 (39)

98 (39)

1.00

26.8 ± 8.2

23.4 ± 9.7

0.09

Tobacco use, % (N)

# of days/past 30
Amount (mg)

315.1 ± 194.7 201.8 ± 169.7

Cannabis use, % (N)

58 (23)

OAT type
Methadone, %
Methadone dose (mg)
Buprenorphine, %
Buprenorphine dose (mg)

53
97.4 ± 33.6
47
12.8 ± 6.0
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13 (5)

0.01
<0.001

Table 3.
Experimental session characteristics
OUD+
(n=40)

OUD(n=40)

p-value

Happy

69.7 ± 22.6

78.9 ± 12.0

<0.01

Anxious

26.5 ± 25.0

13.4 ± 16.8

<0.001

Sad

11.7 ± 18.6

5.0 ± 10.2

<0.01

Sick
Nauseous

5.9 ± 13.2
6.7 ± 13.3

3.6 ± 6.9
1.6 ± 4.1

0.17
<0.001

Hungry

35.5 ± 28.8

33.2 ± 27.9

0.60

9.5 ± 3.0

8.5 ± 1.4

<0.01

Duration between Sessions 1 and 2 (min)

200.5 ± 22.4

191.1 ± 10.4

0.02

Time since last ate (min)

622.0 ± 361.1

368.2 ± 321.1

<0.001

Time since last cigarette (min)

(n=33)
(n=5)
393.0 ± 642.4 1439.6 ± 1980.4

<0.01

(n=27)
(n=9)
4086.3 ± 7412.0 4431.9 ± 7567.5

0.87

Pre-session ratings (0-100)

Session characteristics
Mean session duration (min)

Time since last cannabis use (min)
Mean and standard deviation
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Table 4.
Sucrose subjective response ratings
OUD+
(N=40)

OUD(N=40)

Pleasantness
Intensity
Concentration dose (0M)

49.6 ± 1.3
36.4 ± 2.0

57.5 ± 1.3
39.1 ± 2.0

Pleasantness

28.9 ± 19.4

45.0 ± 12.4

7.4 ± 8.0

3.5 ± 5.1

31.9 ± 17.3
11.1 ± 8.8

46.6 ± 11.5
9.5 ± 11.5

Pleasantness
Intensity

41.4 ± 14.4
22.7 ± 14.2

53.7 ± 9.7
25.5 ± 16.8

Concentration dose (.50M)
Pleasantness
Intensity

53.7 ± 14.9
41.2 ± 21.2

58.9 ± 10.1
45.8 ± 21.8

Concentration dose (.75M)
Pleasantness

59.5 ± 18.2

64.3 ± 12.1

Intensity
Concentration dose (1.0M)

52.2 ± 22.6

55.5 ± 22.5

Pleasantness
Intensity
Mean and standard deviation

61.1 ± 17.2
54.2 ± 23.6

63.4 ± 13.5
58.2 ± 22.7

AUC

Intensity
Concentration dose (.10M)
Pleasantness
Intensity
Concentration dose (.25M)
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Table 5.
Food Frequency Questionnaire: Sweet food and beverage items
OUD+
Food items
(n=40)
Beverages
Tomato or vegetable juice
>1 in past year
30
>1 weekly
10
>1 daily
0
Orange juice and grapefruit juice
>1 in past year
75
>1 weekly
35
>1 daily
5
Apple juice
>1 in past year
70
>1 weekly
45
>1 daily
0
Grape juice
>1 in past year
60
>1 weekly
18
>1 daily
0
Other 100% fruit juice or 100% fruit juice
mixtures (e.g., pineapple, prune)
>1 in past year
73
>1 weekly
38
>1 daily
5
Other fruit drinks (e.g., cranberry cocktail, HI-C,
lemonade, Kool-Aid)
>1 in past year
75
>1 weekly
48
>1 daily
13
Meal replacement, energy,
or high-protein beverages
>1 in past year
33
>1 weekly
18
>1 daily
3
Soft drinks, soda, or pop
>1 in past year
85
>1 weekly
55
>1 daily
38

36

OUD(n=40)

p-value

33
8
3

0.81
0.69
0.31

85
18
0

0.26
0.08
0.15

63
8
0

0.48
<0.001
1.0

28
0
0

<0.01
<0.01
1.0

78
5
0

0.61
<0.001
0.15

48
8
0

0.01
<0.001
0.02

30
15
10

0.81
0.76
0.17

68
20
0

0.07
<0.01
<0.001

Desserts
Frozen yogurt, sorbet, or ices
>1 in past year
>1 weekly
>1 daily
Ice cream, ice cream bars, or sherbet
>1 in past year
>1 weekly
>1 daily
Pudding or custard
>1 in past year
>1 weekly
>1 daily
Cake
>1 in past year
>1 weekly
>1 daily
Cookies or brownies
>1 in past year
>1 weekly
>1 daily
Doughnuts, sweet rolls, Danish, or pop-tarts
>1 in past year
>1 weekly
>1 daily
Sweet muffins or dessert breads
>1 in past year
>1 weekly
>1 daily
Fruit crisp, cobbler, or strudel
>1 in past year
>1 weekly
>1 daily
Pie
>1 in past year
>1 weekly
>1 daily
Chocolate candy
>1 in past year
>1 weekly
>1 daily

37

40
5
0

70
5
0

<0.01
1.0
1.0

88
43
10

98
25
0

0.09
0.10
0.04

68
48
3

35
18
0

<0.01
<0.01
0.31

73
20
3

95
0
0

<0.01
<0.01
0.31

88
10
3

100
0
0

0.02
0.04
0.31

80
48
5

88
18
0

0.36
<0.01
0.15

63
23
0

85
13
0

0.02
0.24
1.0

50
15
0

63
0
0

0.26
0.01
1.0

70
10
0

93
0
0

<0.01
<0.05
1.0

85
55
13

98
48
8

<0.05
0.50
0.46

Other candy
>1 in past year
93
88
0.46
>1 weekly
65
25
<0.001
>1 daily
18
0
<0.01
Sugar/sweeteners added to foods and beverages
Sugar or honey added to coffee or tea
>1 in past year
63
63
1.0
>1 weekly
60
33
0.01
>1 daily
48
10
<0.001
Artificial sweetener added to coffee or tea
>1 in past year
35
8
<0.01
>1 weekly
25
5
0.01
>1 daily
18
5
0.08
Sugar or honey added to foods
>1 in past year
68
60
0.49
>1 weekly
55
30
0.02
>1 daily
33
10
0.01
Jam, jelly, or honey on breads or rolls
>1 in past year
75
75
1.0
>1 weekly
35
15
0.04
>1 daily
8
3
0.30
% of participants endorsing consumption of items at frequency of at least once annually,
weekly, and daily
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Table 6.
Nutrition Knowledge Questionnaire
Knowledge areas assessed

OUD+
(n=40)

OUD(n=40)

p-value

Total items correct, %

45 ± 19

64 ± 12

<0.001

Dietary recommendations

52 ± 19

65 ± 12

<0.001

Awareness of balance of good health food
group proportions

42 ± 27

59 ± 21

<0.01

Awareness of recommendations for
consumption of fruit and vegetables

8 ± 27

23 ± 42

0.06

Awareness to reduce saturated fat

53 ± 51

73 ± 45

0.07

Awareness of which foods experts
recommend eating less or more

61 ± 22

71 ± 12

0.01

Nutrient sources

47 ± 27

67 ± 16

<0.001

Knowledge of sources of oily fish

31 ± 35

38 ± 33

0.32

Knowledge of sources of dietary fiber

51 ± 28

74 ± 17

<0.001

Healthiest meal option

43 ± 31

64 ± 20

<0.001

Sandwich

25 ± 44

25 ± 44

1.00

High-fiber, low-fat meal

35 ± 48

50 ± 51

0.18

Baked potato

60 ± 50

90 ± 30

<0.01

Grilled meat

50 ± 51

93 ± 27

<0.001

Association between diet and disease

29 ± 25

57 ± 23

<0.001

Fiber

13 ± 33

65 ± 48

<0.001

Fruits and vegetables

12 ± 28

30 ± 35

0.01

Fat

44 ± 46

79 ± 34

<0.001

Sugar

37 ± 26

58 ± 27

<0.001

Salt
Mean and SD percent of total items correct

45 ± 50

85 ± 36

<0.001
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Table 7.
Yale Food Addiction Scale criteria
OUD+
(n=40)

OUD(n=40)

p-value

1. Substance taken in larger
amount and for longer
period than intended

8%

0%

0.24

2. Persistent desire or
repeated unsuccessful
attempts to quit

93%

83%

0.18

3. Much time/activity to
obtain, use, recover

23%

13%

4. Important social,
occupational, or
recreational activities given
up or reduced

25%

0%

<0.01

5. Use continues despite
knowledge of adverse
consequences

20%

13%

0.36

6. Tolerance

38%

10%

<0.01

7. Characteristic withdrawal
symptoms

15%

3%

0.12

Criteria

8. Use causes clinically
significant impairment or
10%
3%
distress
% of participants meeting each Yale Food Addiction Scale criterion

40

0.24

0.62

Figure Legends
Figure 1. Schematic illustrating experimental session procedures
Figure 2. Sucrose pleasantness (upper panel) and intensity (bottom panel) ratings
between OUD+ (circles) and OUD- (squares) participants. Error bars represent SEM and
asterisks indicate significant between-group differences in ratings at each sucrose
concentration. Filled symbols indicate significant within-group differences in ratings at
each concentration from placebo (0M), while unfilled indicates that ratings are not
significantly different from placebo.
Figure 3. Change from placebo (0M sucrose concentration) in sucrose pleasantness
(upper panel) and intensity (lower panel) ratings between OUD+ (circles) and OUD(squares) participants. Error bars represent SEM and asterisks indicate significant
between-group differences in change in ratings from placebo at each sucrose
concentration. Filled symbols indicate significant within-group differences in change in
ratings at each concentration from placebo (0M), while unfilled indicates that the change
in ratings are not significant from placebo. Y-axes are represented on a smaller scale to
permit a more detailed inspection of data.
Figure 4. Percent of OUD+ vs. OUD- participants in normal, overweight, and obese
BMI categories. Asterisks indicate significant between-group differences.
Figure 5. Prevalence of past-year food insecurity between OUD+ vs. OUD- participants
and percent of OUD+ and OUD- participants across the 4 USDA food security categories
(high, marginal, low, and very low). Asterisks indicate significant between-group
differences.
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Figure 6. Mean frequency ratings on the 12 items of the Eating Behavior Ratings
Questionnaire between OUD+ vs. OUD- participants (top panel) and mean ratings on the
9 food items among OUD+ vs. OUD- participants that endorsed that they felt like
consuming (middle and bottom panel). The middle panel displays mean eagerness
ratings and the bottom panel displays mean amount of consuming the food items. Error
bars represent SEM and asterisks indicate significant between-group differences.
Figure 7. Mean amount of added sugar from caffeinated beverages consumed per day
(g/day) among OUD+ vs. OUD- participants. An asterisk indicates significant betweengroup differences.
Figure 8. Comparison in the percent of OUD+ vs. OUD- participants endorsing
problems with foods on the Yale Food Addiction Scale. The upper panel represents the
percent of participants endorsing problems with the 7 high-sugar items and the bottom
panel presents the percent of participants endorsing problems with the 7 high-fat items.
Asterisks indicate significant between-group differences.
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Figure 1.

Sucrose Taste Test

Presession
questions

A

B

C

D

E

F

B

C D E

F

A

C

D E

Between samples:
• Rate pleasantness and intensity on VAS
• Rinse mouth with water
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Figure 2.
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Figure 3.
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Figure 4.

BMI Categories
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Figure 5.

Food Security
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Figure 6.
Eating Behavior Ratings:
Items 1-12
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Figure 7.

Sugar in Caffeinated Beverages Consumption
OUD+ (n=40)
OUD- (n=40)
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Figure 8.

Yale Food Addiction Scale
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